Hitri A, Hurd Y L, Wyatt R J, Deutsch S I
NIDA Research Unit, Department of Veterans Affairs Medical Center, Washington, D.C. 20422.
Clin Neuropharmacol. 1994 Feb;17(1):1-22. doi: 10.1097/00002826-199402000-00001.
The carrier molecule that transports dopamine (DA) across the synaptic membrane is known as the dopamine transporter (DAT). Depending on the ionic conditions, DAT may function as a mediator of both the inward directed DA transport known as the "reuptake" and the outward directed DA transport known as the "release." The functional significance of DAT is in the regulation of DA neurotransmission by terminating the action of DA in the synapse via reuptake. With use of DAT binding as a presynaptic marker to measure altered DA innervation, abnormalities of the DAT binding have been demonstrated in idiopathic Parkinson's disease, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity, and progressive supranuclear palsy. Moreover, the identification of DAT as the neuronal element that mediates the addictive properties of cocaine highlights its significance in cocaine addiction. Cocaine binding in the brain is heterogeneous, and there is an uneven distribution of the high- and low-affinity binding sites across the anatomical regions. Regional differences in ligand binding are observed by using both [3H]cocaine and the diphenyl-substituted piperazine derivatives known as the "GBR series" of ligands. The identification of compounds that inhibit the binding of medications for cocaine abuse. Furthermore, clarification of the various binding domains that may be relevant to transporter function in human neuropsychiatric disorders may lead to the development of new medications for schizophrenia, Tourette's disease, and drug addiction.
将多巴胺(DA)转运穿过突触膜的载体分子被称为多巴胺转运体(DAT)。根据离子条件,DAT可能作为被称为“再摄取”的内向DA转运和被称为“释放”的外向DA转运的介质。DAT的功能意义在于通过再摄取终止突触中DA的作用来调节DA神经传递。通过使用DAT结合作为突触前标记来测量DA神经支配的改变,已在特发性帕金森病、1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)神经毒性和进行性核上性麻痹中证实了DAT结合的异常。此外,将DAT鉴定为介导可卡因成瘾特性的神经元元件突出了其在可卡因成瘾中的重要性。大脑中的可卡因结合是异质性的,高亲和力和低亲和力结合位点在解剖区域的分布不均匀。通过使用[3H]可卡因和被称为“GBR系列”配体的二苯基取代哌嗪衍生物观察到配体结合的区域差异。鉴定抑制可卡因滥用药物结合的化合物。此外,阐明在人类神经精神疾病中可能与转运体功能相关的各种结合域,可能会导致开发用于治疗精神分裂症、妥瑞氏症和药物成瘾的新药。